Postural orthostatic tachycardia syndrome: the Mayo clinic experience
- PMID: 17352367
- DOI: 10.4065/82.3.308
Postural orthostatic tachycardia syndrome: the Mayo clinic experience
Abstract
Objective: To evaluate the prevalence and pathogenetic mechanisms of postural orthostatic tachycardia syndrome (POTS).
Patients and methods: We reviewed the medical records of patients with POTS seen at the Mayo Clinic in Rochester, Minn, from January 1, 1993, through December 31, 2003. All patients were required to have had a full autonomic reflex screen. The results of the following additional tests were evaluated: thermoregulatory sweat test, plasma catecholamine measurement, serum ganglionic (a3) acetylcholine receptor antibody detection, and 24-hour urinary sodium measurement.
Results: We identified 152 patients (86.8% female; mean +/- SD age, 30.2+/-10.3 years) with a mean duration of symptoms of 4.1 years. The mean orthostatic heart rate increment was 44 beats/min. Half the patients had sudomotor abnormalities (apparent on both the quantitative sudomotor axon reflex test and thermoregulatory sweat test), and 34.9% had significant adrenergic impairment, indicating that at least half of the patients had a neuropathic pattern of POTS. In 13.8% of patients, onset was subacute, and ganglionic acetylcholine receptor antibody was detected in 14.6%, suggesting an autoimmune origin in at least 1 in 7 patients. Hyperadrenergic status was documented in 29.0% of patients (standing plasma norepinephrine level 2600 pg/mL), and at least 28.9% were presumably hypovolemic (24-hour urinary sodium level <100 mEq/24h). The lack of correlation between urinary sodium and standing norepinephrine levels suggests that mechanisms other than hypovolemia accounted for the hyperadrenergic state.
Conclusion: Our findings suggest a neuropathic basis for at least half the cases of POTS and that a substantial percentage of cases may be autoimmune. Hyperadrenergic and hypovolemic correlates are likely compensatory or exacerbating.
Similar articles
-
Standardized Autonomic Testing in Patients With Probable Radiation-Induced Afferent Baroreflex Failure.Hypertension. 2022 Jan;79(1):50-56. doi: 10.1161/HYPERTENSIONAHA.121.17805. Epub 2021 Nov 5. Hypertension. 2022. PMID: 34739766 Free PMC article.
-
Distal sudomotor findings in postural tachycardia syndrome.Clin Auton Res. 2010 Apr;20(2):93-9. doi: 10.1007/s10286-009-0045-y. Epub 2009 Dec 25. Clin Auton Res. 2010. PMID: 20035362 Free PMC article.
-
Skin Biopsy and Quantitative Sudomotor Axon Reflex Testing in Patients With Postural Orthostatic Tachycardia Syndrome.Cureus. 2022 Nov 2;14(11):e31021. doi: 10.7759/cureus.31021. eCollection 2022 Nov. Cureus. 2022. PMID: 36349067 Free PMC article.
-
The postural tachycardia syndrome.Cardiol Rev. 2007 Mar-Apr;15(2):67-75. doi: 10.1097/01.crd.0000233768.68421.40. Cardiol Rev. 2007. PMID: 17303993 Review.
-
Neurogenic orthostatic hypotension: a pathophysiological approach.Circulation. 2009 Jan 6;119(1):139-46. doi: 10.1161/CIRCULATIONAHA.108.805887. Circulation. 2009. PMID: 19124673 Free PMC article. Review. No abstract available.
Cited by
-
Gender Diversity Among Youth Attending an Intensive Interdisciplinary Pain Treatment Program.J Clin Psychol Med Settings. 2024 Jan 24. doi: 10.1007/s10880-023-09997-7. Online ahead of print. J Clin Psychol Med Settings. 2024. PMID: 38265699
-
Symptom presentation by phenotype of postural orthostatic tachycardia syndrome.Sci Rep. 2024 Jan 2;14(1):205. doi: 10.1038/s41598-023-50886-8. Sci Rep. 2024. PMID: 38168762 Free PMC article.
-
Poincaré plot can help predict the curative effect of metoprolol for pediatric postural orthostatic tachycardia syndrome.Front Neurosci. 2023 Nov 14;17:1280172. doi: 10.3389/fnins.2023.1280172. eCollection 2023. Front Neurosci. 2023. PMID: 38033543 Free PMC article.
-
Head-down tilt reduces the heart rate in postural tachycardia syndrome in acute setting: a pilot study.Neurol Sci. 2023 Nov 3. doi: 10.1007/s10072-023-07153-5. Online ahead of print. Neurol Sci. 2023. PMID: 37919442
-
Dysautonomia, Hypermobility Spectrum Disorders and Mast Cell Activation Syndrome as Migraine Comorbidities.Curr Neurol Neurosci Rep. 2023 Nov;23(11):769-776. doi: 10.1007/s11910-023-01307-w. Epub 2023 Oct 17. Curr Neurol Neurosci Rep. 2023. PMID: 37847487 Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
